School of Pharmacy
About the school:
Through collaborating with UCL School of pharmacy, ranking 8th on the world, Newgiza University utilizes existing UCL teaching and assessment resources, delivering the NGU program that produces distinctive NGU Pharmacists.
The BPharm (PharmD) program at NGU aims at graduating scientifically literate, research-informed, patient-centered, and socially responsible professionals who can serve the pharmaceutical needs of individuals and communities both in Egypt and abroad.
Meet the Dean
Dr. Manal Maher,
Dean School of Pharmacy
Prof. Manal Mohamed Maher Hussein, Dean of the Faculty of Pharmacy- Newgiza University and professor of microbiology and immunology. She held several positions at Faculty of Pharmacy- Cairo University including, Acting Dean (7/2014-12/2014); Vice-Dean for Education and Students Affairs (2011-2016); Coordinator of the Clinical Pharmacy Program (2009-2011). She participated in the implementation of the Clinical Pharmacy Program, until the first graduated class in 2011. She is a member of the Promotion Committee of Professors and Associate Professors for Microbiology and Immunology.
Her research areas of interest are microbial resistance, fermentation technology and development of new vaccines and biotechnological products.
Dr. Manal was the PI investigator in two research projects covering the process development for the industrial production of Rifamycin B and the feasibility study for a cost-effective process for the production of Rifamycin B. Awarded a Patent No. (200312062) titled “Process for Production of Rifamycin B using improved bacterial strain”.
NGU is offering a large number of generous merit scholarships for bright students interested in studying pharmaceutical sciences and clinical pharmacy.
Admitted students meeting the scholarship criteria will enjoy tuition waivers varying from 100% to 25% based on their high school grades, English proficiency, interview, and extracurricular activities.
To celebrate the inauguration of the school of Engineering, a significant percentage of the first cohort will receive merit scholarships.
To be eligible for the scholarship scheme offered by NGU:
- Students must fulfill the requirements of the supreme council of universities for admission.
- Students should fulfill NGU admission requirements.
The deadline for applying for the scholarship has been extended to 15 September 2021.
How to Apply
Accreditation & Academic Collaboration
Endorsed by Presidential Decree on April 2010, NGU initially focused on the launching of three main schools: Medicine, Pharmacy, and Dentistry.
The university first opened its doors in 2016, and since then, its schools have been witnessing a continual growth including fields other than healthcare, until it became a truly multidisciplinary university. NGU’s ongoing collaborations with globally-ranked academic institutions further cemented its growing reputation as a professional institute of higher education.
University College London (UCL):
The academic collaboration between UCL and NGU was centered on NGU’s School of Health Sciences, enhancing NGU’s academic capabilities, as well as offering world-renowned undergraduate programs, providing both school and students with ample opportunities for development on an academic and personal levels.
This collaboration ensured that the highest international standards in teaching and research are met at NGU, with highly qualified faculty members providing instruction and supervision, starting at first with three schools: School of Medicine in collaboration with UCL Medical School, School of Pharmacy in collaboration with UCL School of Pharmacy, and School of Dentistry in collaboration with UCL Eastman Dental Clinic.
Being London’s ‘global university’, University College London (UCL) has a distinguished presence in Australia and Qatar, as well as partnerships around the world with a host of leading educational bodies, from Berkeley to Yale, and Peking University to the University of Sydney, UCL’s influence spans the globe, with such accreditations, it brought its worldwide expertise to NGU.
Having Currently ranked 7th on the QS World University Rankings, and consistently placing in the Top 20 of various global university rankings, UCL is widely recognized for its research capabilities and contributions to scholarships and innovations. The university boasts 29 Nobel Prize winners and is the 2nd most cited university in Europe, as of 2016.
Right at the heart of the Giza Plateau and within touching distance of the Great Pyramids, UCL’s professors, lecturers, and staff lead the brightest young minds forward towards successful careers in their chosen field. UCL focuses on personal development and intellectual growth through typically small class sizes maintaining a low staff to student ratio, in line with the tutorial-based teaching methods employed by UCL globally. Constant student engagement on both a scholarly and extra-curricular level ensured a heightened learning experience, spurring every student towards discovering their true potential and realizing NGU’s goal of achieving truly unbounded thinking.
Acknowledgment letter: to add a recommendation letter from a Math or Physics teacher for all school degrees.
- American diploma: 8 main subjects required from the school transcript including Biology, Chemistry, Physics, English, and Math, SAT I /ACT I/EST I is required and SAT II/ACT IIEST II is not mandatory but increase the overall percentage.
- IGCSE: 8 O levels including Biology, Chemistry, Physics, English, and Math.
- IB: Biology and Chemistry high level and English and Math High Level or standard level (the applicants are waived from the Physics).
- Canadian: 8 subjects including Biology, Chemistry, Physics, English, and Math.
The NGU BPharm (PharmD) is five academic years in duration (10 semesters) and a year of residency training (year of excellence). This includes an Introductory Semester that is shared with other health education programs at NGU (Medicine and Dentistry). Successful completion of the five-year program and spending the year of residency training (year of excellence), will result in the award of the BPharm (PharmD).
The program contains 198 credit units (20 credit units per semester for 9 semesters, plus 18 credit units for the introductory semester). These credit units do not represent only contact hours but the total learning effort required to achieve the learning outcomes including direct contact hours in classrooms, small groups and practical classes, workplace-based learning in clinical placements, project work and self-directed learning. A credit unit is considered to be equivalent to 25-30 hours of study time.
The assessment approach has been designed alongside the curriculum that embraces the following key principles:
a) Formative assessment: Students take formative tests throughout the modules running all through the program.
b) Summative assessments: May take the form of written examinations, coursework, portfolio or reports (e.g. Elective) at the end of each semester.
c) Practical/Objective: Structured Clinical Examinations (P/OSCEs)
Year 1: Semester 1: Introductory module
Semester 1: Introductory module (IM 1.1.1)
Includes underpinning basic sciences, basic communication skills, English language skills, in addition to orientation for a career in healthcare.
Year 1: Semester 2:
PHAR101: The role of pharmacists in health care
Introduces students to their future role as pharmacists and to the current and evolving pharmacy profession. A “Top 25” drug list is introduced.
PHAR102: Body systems and therapeutics 1.
Provides a solid foundation of the biological sciences that underpin the clinical therapeutic uses of a drug, also introducing and discussing cell biology and biochemistry, cell and organ system function, whole-body physiology and pharmacology.
Year 2: Semester 1
PHAR 201: Chemistry of medicines
Provides a solid foundation of the chemical sciences underpinning the use of a drug in its broadest sense, in addition to introducing and discussing organic, physical and analytical chemistry concepts in detail.
PHAR 202: Making safe and effective medicines
Formulation and manufacture of safe and effective medicines, both sterile and non-sterile, with particular emphasis on liquid and semi-solid systems.
Year 2: Semester 2:
PHAR 203: Clinical and professional considerations
The knowledge, skills, and attitudes required for pharmacy practice are further developed throughout the module.
The “Top 25” drugs will be extended to a “Top 50”
PHAR 204: Body Systems and Therapeutics 2
Concentrates on the cardiovascular, renal, and endocrine systems, providing a solid underpinning knowledge of the structure and function of these body systems. Discussing the concept of clinical therapeutics, demonstrating how drug utilization is firmly grounded in the pharmaceutical and pharmacological sciences.
Year 3: Semester 1
PHAR 301: Body Systems and Therapeutics 3
Focuses on the central nervous system; gastro-intestinal system, liver, skin and eye, and at the same time providing a solid underpinning knowledge of the structure and function of these body systems.
PHAR 302: Medicines from the bench to the clinic
Describes the processes involved in the discovery, development, and testing of a new molecule, i.e. its journey from the laboratory bench to clinical use.
Year 3: Semester 2
PHAR 303: Body Systems and Therapeutics 4
Focuses on the immune system, disease relating to inflammation, infectious diseases, respiratory diseases, and cancer, providing a solid foundation of the relevant biological principles.
PHAR 304: Communicating science and practice
Further prepares students for their future role as pharmacists for the current and evolving pharmacy profession.
The “Top 50” drug list is extended in this module to a “Top 75”.
Year 4: Semester 1
PHAR 401: Future design and delivery of medicines
Explores some of the more advanced technologies used in the discovery and formulation of new drug molecules and production of the formulated product.
PHAR 402: Life skills and professional skills
Sound knowledge of research methodology is vital for modern healthcare professionals, as is the ability to apply research and evaluative skills in practice. This module also develops students’ personal skills in areas such as written and oral communication.
Year 4: Semester 2
PHAR 403: Options (Electives)
Each student selects two options; one from strand A which comprises broad areas, whereas strand B comprises specific topics.
PHAR 404: Experiential placement
An experiential placement is a mandatory requirement for graduation in Egypt, hence, this ensures that suitable high-quality experiences are available for all students.
Year 5: Semester 1
PHAR 501: Independent research project
Includes the design, implementation, and delivery of a research project. The projects may be laboratory-based or practice-based or data/literature/theory-based. Each student has an individual project and is assessed individually.
Year 5: Semester 2
PHAR 502: Advancing practice through science
New advances in science and practice while revisiting topics previously covered in the course.
PHAR 503: Preparation for professional practice
Describes current and future roles in pharmacy and prepares students for practice.
The “Top 75” drugs list is extended to a “Top 100”.
Year 6: (year of residency training) (year of excellence)
Waiting for instructions and specifications from The Supreme Council of Universities in Egypt.
SOP currently has two state-of-the-art research facilities, where multi-disciplinary research groups are able to conduct ground-breaking research.
|1. Pharmacotherapy role in improvement of disease outcomes|
|2. Therapeutic Drug Monitoring.|
|3. Drug interactions.|
|7. Herbal medicines and tissue culture.|
|8. Standardization of drugs.|
|9. Formulation and evaluation of nano-drug delivery systems.|
|10. Biopharmaceuticals (Biosimilars, Bioinformatics, Gene therapy, and recombinant DNA).|
|11. Water resources.|
|13. Hepatic diseases.|
|14. Metabolic disorders (Obesity and Diabetes).|
|15. Cardiovascular diseases (Hypertension).|
|16. Central nervous system and neurodegenerative diseases.|
|17. Infectious diseases.|
|18. Development and fabrication of Advanced Drug Delivery.|
|19. Targeted Drug Delivery systems.|
|20. Biopharmaceutics and Pharmacokinetics optimization.|
|21. Patient centric formulations.|
Projects and Grants:
1. ASRT, Academy of Scientific Research and Technology, Egypt
Ahmed S. Attia (PI), Medhat Al-Ghobashy & Noha Elhosseiny
“The production of nanobodies using the yeast display technology as a non-conventional tool for precision medicine in infective diseases & beyond”
December 2020 – Running
2. ASRT, Academy of Scientific Research and Technology, Egypt
Grant Code: KTA-C4-4267
“Towards the Establishment of a Globally Compliant Egyptian Active Pharmaceutical Ingredient Facility for Critical Diseases”
April 2020 – Running
3. STDF-RSG, Science & Technology Development Fund, Egypt
Grant Code: 34848
“Development of Novel EGF Receptor Inhibitors Targeting Non-Small Cell Lung Cancer (NSCLC)”
October 2019 – Running
4. STDF-RSG, Science & Technology Development Fund, Egypt
Grant Code: 30069
“Design, Synthesis, and Biological Evaluation of Novel Raf -1/VEGFR-2 Inhibitors as Antiangiogenic Agents”
October 2019 – Running
5. STDF-RSG, Science & Technology Development Fund, Egypt
Grant Code: 34859
“Synthesis and biological evaluation of novel fibrates as antihyperlipidemic agents”
October 2019 – Running
6. STDF, Science & Technology Development Fund, Egypt
Medhat Al-Ghobashy (PI), Ahmed Attia (Co-PI), Basma Eltanany & Mohamed Abdullah
“Assessment of biosimilarity and interchangeability of locally produced biopharmaceuticals using statistically-guided orthogonal testing protocols at industrial scale”
May 2019 – Running
7. ASRT, Academy of Scientific Research and Technology, Egypt
Nesrine Salah El Dine El-Sayed (PI), Salwa Ahmed Elgebaly, Medhat Al-Ghobashy, Galal Elgemeie & Mamdouh A. Abu-Zaied
“To Determine the Capability of the Cardioprotective Cyclocreatine Phosphate to Reduce the Progression of Myocardial Infarction to Heart Failure in the Standard ISO Rat Model”
November 2018 – Running
8. Bilateral project: NRC, National Research Centre & CNR, Istituto di Chimica del Riconoscimento Molecolare
Project code: IT II 020702
“Design, Synthesis and Biological Evaluation of Novel Chalcone-based Fibrates as Novel PPAR-α Agonists”
March 2018 – Closed.
9. STDF, Science & Technology Development Fund, Egypt
Project code: STDF 15063
“Development of Novel VEGF Tyrosine Kinase Receptor Antagonists Utilizing Molecular Modeling Techniques”
March 2017 – Closed.
10. STDF, Science & Technology Development Fund, Egypt
Medhat Al-Ghobashy (PI), Aliaa El-Meshad (Co-PI), Ahmed Attia, Wael Mamdouh, Muhammad Al-Shorbagy, & Mohamed Abduallah
“Formulation and Evaluation of Surface Functionalized Nanoparticles Enclosing Myelin Basic Protein for Treatment of Multiple Sclerosis”
April 2016 – Closed.
- Hany H. Arab, Muhammad Y. Al-Shorbagy, Muhammed A. Saad. “Activation of autophagy and suppression of apoptosis by dapagliflozin attenuates experimental inflammatory bowel disease in rats: Targeting AMPK/mTOR, HMGB1/RAGE and Nrf2/HO-1 pathways”, Chemico-Biological Interactions, 335, 109368, (2021), ISSN 0009-2797.
https://doi.org/10.1016/j.cbi.2021.109368. IF: 3.723
- El-Yamany, Muhammed F., Eman S. Zaki, Sherif A. Shaltout, and Muhammed A. Saad. “Bone marrow mononuclear cells boosts anti-cytogentical aberration effect of N-Acetylcysteine and α-lipoic acid in rat’s liver and bone marrow: Implication of oxidative and inflammatory pathways”, Toxicology Mechanisms and Methods, 1-13, (2021).
- Muhammed A. Saad, Maha A. E. Ahmed, Norhan N. Elbadawy, Noha F. Abdelkader. “Nano-Ivabradine Averts Behavioral Anomalies in Huntington’s Disease Rat Model via Modulating Rhes/m-Tor Pathway.”, Progress in Neuropsychopharmacology & Biological Psychiatry, 111, 110368, (2021).
- Rofida A. Saleh, Tarek F. Eissa, Dalaal M. Abdallah, Muhammed A. Saad, Hanan S. El- Abhar. “Peganum harmala enhanced GLP-1 and restored insulin signaling to alleviate AlCl3-induced Alzheimer-like pathology model.” Scientific reports, 11, 12040, (2021).
https://doi.org/10.1038/s41598-021-90545-4. IF: 3.998
- Amr M. Emam, Muhammad A. Saad, Naglaa A. Ahmed, Hala F. Zaki. “Vortioxetine mitigates neuronal damage by restricting PERK/eIF2α/ATF4/CHOP signaling pathway in rats subjected to focal cerebral ischemia-reperfusion”, Life Sciences, 283, 119865, (2021), ISSN 0024-3205.
https://doi.org/10.1016/j.lfs.2021.119865. IF: 5.037
- Shouman, Maha M., Rania M. Abdelsalam, Mahmoud M. Tawfick, Sanaa A. Kenawy, and Mona M. El-Naa. “Antisense Tissue Factor Oligodeoxynucleotides Protected Diethyl Nitrosamine/Carbon Tetrachloride-Induced Liver Fibrosis Through Toll Like Receptor4-Tissue Factor-Protease Activated Receptor1 Pathway.”, Frontiers in Pharmacology, 12, 1140, (2021), ISSN 1663-9812.
https://doi.org/10.3389/fphar.2021.676608. IF: 3.845
- Abo-zalam, Hagar B., Ezzeldein S. El-Denshary, Rania M. Abdelsalam, Islam A. Khalil, Mahmoud M. Khattab, and Mohamed A. Hamzawy. “Therapeutic advancement of simvastatin-loaded solid lipid nanoparticles (SV-SLNs) in treatment of hyperlipidemia and attenuating hepatotoxicity, myopathy and apoptosis: Comprehensive study.”, Biomedicine & Pharmacotherapy, 139, 111494, (2021), ISSN 0753-3322.
https://doi.org/10.1016/j.biopha.2021.111494. IF: 4.545
- Salem, Wadhah Atef, Elkady, Ehab Farouk, Fouad, Marwa Ahmed, Abdul-Azim Mohammad, Mohammad. “Analysis of Metformin and Five Gliptins in Counterfeit Herbal Products: Designs of Experiment Screening and Optimization”, Journal of AOAC INTERNATIONAL, qsab106, (2021), SN 1060-3271
- Farag MM, Abd El Malak NS, Yehia SA, Ahmed MA. “Hyaluronic Acid Conjugated Metformin-Phospholipid Sonocomplex: A Biphasic Complexation Approach to Correct Hypoxic Tumour Microenvironment”, Int J Nanomedicine, 16, 1005-1019, (2021).
Doi: 10.2147/IJN.S297634. IF: 5.115
- Mohamed Abdallah Ahmed, Wedian Younis Abdelgawad, Mary Kamal Gad, Magdy Ibrahim Mohamed. “A novel approach for the treatment of oral ulcerative lesion using mucoadhesive proniosome gel”, Journal of Drug Delivery Science and Technology, 102460, (2021), ISSN 1773-2247.
https://doi.org/10.1016/j.jddst.2021.102460. IF: 2.734
- Ramadan, E.B. Basalious and M. Abdallah. “Industrial application of QbD and NIR chemometric models in quality improvement of immediate release tablets”, Saudi Pharmaceutical Journal, (2021), ISSN 1319-0164.
https://doi.org/10.1016/j.jsps.2021.04.012. IF: 2.879
- Abdelmonem R, Elhabal SF, Abdelmalak NS, El-Nabarawi MA, Teaima MH. “Formulation and Characterization of Acetazolamide/Carvedilol Niosomal Gel for Glaucoma Treatment: In Vitro, and In Vivo Study.”, Pharmaceutics, 13(2), 221, (2021).
- Farag MM, Abd El Malak NS, Yehia SA, Ahmed MA. “Hyaluronic Acid Conjugated Metformin-Phospholipid Sonocomplex: A Biphasic Complexation Approach to Correct Hypoxic Tumour Microenvironment.”, Int J Nanomedicine., 16, 1005-1019, (2021).
Doi:10.2147/IJN.S297634. IF: 5.115
- Abdalla R. Mohamed, Ahmed M. El Kerdawy, Riham F. George, Hanan H. Georgey, Nagwa M. Abdel Gawad. “Design, synthesis and in silico insights of new 7,8-disubstituted-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione derivatives with potent anticancer and multi-kinase inhibitory activities”, Bioorganic Chemistry, 107, 104569, (2021), ISSN 0045-2068.
https://doi.org/10.1016/j.bioorg.2020.104569. IF: 4.831
- Eldehna WM, Al-Rashood ST, Al-Warhi T, Eskandrani RO, Alharbi A, El Kerdawy AM. “Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and in silico studies”, J Enzyme Inhib Med Chem, 36(1), 270-285, (2021).
Doi: 10.1080/14756366.2020.1862101. IF: 4.673
- Rasha M. Hassan, Mona E. Aboutabl, Manuela Bozzi, Mohammed F. El-Behairy, Ahmed M. El Kerdawy, Beatrice Sampaolese, Claudia Desiderio, Federica Vincenzoni, Francesca Sciandra, Iman A.Y. Ghannam. “Discovery of 4-benzyloxy and 4-(2-phenylethoxy) chalcone fibrate hybrids as novel PPARα agonists with anti-hyperlipidemic and antioxidant activities: Design, synthesis and in vitro/in vivo biological evaluation”, Bioorganic Chemistry,115, 105170, (2021).
Doi: 10.1016/j.bioorg.2021.105170 IF: 5.725
- Heba Ibrahim, A. Abdo, Ahmed M. El Kerdawy, A. Sharaf Eldin. “Signal Detection in Pharmacovigilance: A Review of Informatics-driven Approaches for the Discovery of Drug-Drug Interaction Signals in Different Data Sources”, Artificial Intelligence in the Life Sciences, 1, 100005, (2021).
- Peter A. Halim, Hanan H. Georgey, Mina Y. George, Ahmed M. El Kerdawy, Mona F. Said. “Design and synthesis of novel 4-fluorobenzamide-based derivatives as promising anti-inflammatory and analgesic agents with an enhanced gastric tolerability and COX-inhibitory activity”, Bioorganic Chemistry,115, 105253, (2021).
Doi: 10.1016/j.bioorg.2021.105253 IF: 5.725
- Heba Ibrahim, Ahmed M. El Kerdawy, A. Abdo, A. Sharaf Eldin “Similarity-based machine learning framework for predicting safety signals of adverse Drug–Drug interactions”, Informatics in Medicine Unlocked, 100669, (2021).
Doi: 10.1016/j.imu.2021.100699. IF: 2.110
- Amer MA, Wasfi R, Attia AS, Ramadan MA. “Indole Derivatives Obtained from Egyptian Enterobacter sp. Soil Isolates Exhibit Antivirulence Activities against Uropathogenic Proteus mirabilis”, Antibiotics, 10(4), 363, (2021).
https://doi.org/10.3390/antibiotics10040363. IF: 3.893
- Elhosseiny, Noha M., Tamer M. Samir, Aliaa A. Ali, Amani A. El-Kholy, and Ahmed S. Attia. “Development of an Immunochromatographic Strip Using Conjugated Gold Nanoparticles for the Rapid Detection of Klebsiella pneumoniae Causing Neonatal Sepsis” Pharmaceutics,13(8), 1141, (2021).
https://doi.org/10.3390/pharmaceutics13081141. IF: 6.321
- Nageeb El-Helaly, S.; Abd-Elrasheed, E.; Salim, S.A.; Fahmy, R.H.; Salah, S.; EL-Ashmoony, M.M. “Green Nanotechnology in the Formulation of a Novel Solid Dispersed Multilayered Core-Sheath Raloxifene-Loaded Nanofibrous Buccal Film; In Vitro and In Vivo Characterization”, Pharmaceutics, 13, 474, (2021).
- El-Haddad AE, El-Deeb EM, Amer AA, Saadeldeen AM, Ahmed FM, Salem MA, Taha HS. “Bioactive Phytoconstituents of Morus Plants exhibiting Numerous Therapeutic Activities”, Egyptian Journal of Chemistry, (2021).
- El-Mancy, Shereen S., Alaadin E. El-Haddad, Walaa A. Alshareef, Amr M. Saadeldeen, Soad Z. El-Emam, and Osama S. Elnahas. “Enhancement of Antimicrobial and Antiproliferative Activities of Standardized Frankincense Extract Using Optimized Self-Nanoemulsifying Delivery System”, Scientia Pharmaceutica,89(3), 36, (2021).
- Abd El-Aal, May A., Medhat A. Al-Ghobashy, and Yasser S. El-Saharty. “Preparation and characterization of 96-well microplates coated with molecularly imprinted polymer for determination and biosimilarity assessment of recombinant human erythropoietin.”, Journal of Chromatography A, 1641, 462012, (2021), ISSN 0021-9673.
https://doi.org/10.1016/j.chroma.2021.462012. IF: 4.049
- Nadim, Ahmed H., May A. Abd El-Aal, Medhat A. Al-Ghobashy, and Yasser S. El-Saharty. “Facile imprinted polymer for label-free highly selective potentiometric sensing of proteins: case of recombinant human erythropoietin.”, Analytical and Bioanalytical Chemistry, 413, 3611–3623, (2021).
https://doi.org/10.1007/s00216-021-03325-4. IF: 3.637
- Nadim, Ahmed H., May A. Abd El-Aal, Medhat A. Al-Ghobashy, and Yasser S. El-Saharty. “Optimization of Polydopamine Imprinted Polymer for Label Free Sensitive Potentiometric determination of Proteins: Application to Recombinant Human Erythropoietin Sensing in Different Matrices.”, Microchemical Journal, 167, 106333, (2021), ISSN 0026-265X.
https://doi.org/10.1016/j.microc.2021.106333. IF: 3.594
- Gamal, Mohammed, Heba-Alla H. Abd-ElSalam, Ibrahim A. Naguib, Medhat A. Al-Ghobashy, Hala E. Zaazaa, and M. Abdelkawy. “Green and cost-effective extraction techniques of quercetin from mixture of nutraceuticals with yield analysis via spectrophotometry and high performance liquid chromatograph methods.”, Journal of AOAC International, 18:qsab071, (2021).
DOI: 10.1093/jaoacint/qsab071. IF: 1.510
- Mahdally, N. H., George, R. F., Kashef, M. T., Al-Ghobashy, M., Murad, F. E., & Attia, A. S. “Staquorsin: A Novel Staphylococcus aureus Agr-Mediated Quorum Sensing Inhibitor Impairing Virulence in vivo Without Notable Resistance Development”, Frontiers in microbiology, 12, 700494, (2021).
https://doi.org/10.3389/fmicb.2021.700494. IF: 5.640
- Muhammed A. Saad, Muhammad A. Eltarzy, Rania M. Abdel Salam, Maha A.E. Ahmed. “Liraglutide mends cognitive impairment by averting Notch signaling pathway overexpression in a rat model of polycystic ovary syndrome”, Life Sciences, 265, 118731, (2021), ISSN 0024-3205.
https://doi.org/10.1016/j.lfs.2020.118731. IF: 3.647
- Saad, Muhammad AE, Mohamed IM Fahmy, Rabab H. Sayed, Muhammad F. El‐Yamany, Reham El‐Naggar, Ahmed AE Hegazy, and Muhammad Al‐Shorbagy. “Eprosartan: A closer insight into its neuroprotective activity in rats with focal cerebral ischemia–reperfusion injury.”, Journal of Biochemical and Molecular Toxicology, (2021).
https://doi.org/10.1002/jbt.22796. IF: 3.606
- Nour El-Din HT, Elhosseiny NM, El-Gendy MA, Mahmoud AA, Hussein MMM, Attia AS. “A Rapid Lysostaphin Production Approach and a Convenient Novel Lysostaphin Loaded Nano-emulgel; As a Sustainable Low-Cost Methicillin-Resistant Staphylococcus aureus Combating Platform”, Biomolecules. 10(3), 435, (2020).
https://doi.org/10.3390/biom10030435. IF: 4.694
- Nadia G. Zaki, Walaa H. Mahmoud, Ahmed M. El Kerdawy, Abanoub Abdullah, Gehad G. Mohamed. “Structural Characterization, Thermal Analyses, Antiproliferative and Antimicrobial Activity of Cocaine Complexes with Mn(II) and Cu(II)”, Egyptian Journal of Chemistry, 63(5), 1857-1868, (2020).
DOI: 10.21608/ejchem.2019.16748.2019. IF: 0.966
- Nadia G. Zaki, Walaa H. Mahmoud, Ahmed M. El Kerdawy, Abanoub Mosaad Abdallah, Gehad G. Mohamed. “Heteroleptic complexes of cocaine/TMEDA with some f block metals: Synthesis, DFT studies, spectral, thermal, cytotoxicity and antimetastatic properties”, Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 229, 117938, (2020), ISSN 1386-1425.
https://doi.org/10.1016/j.saa.2019.117938. IF: 3.232
- Ehab M. Gedawy, Asmaa E. Kassab, Ahmed M. El Kerdawy. “Design, synthesis and biological evaluation of novel pyrazole sulfonamide derivatives as dual COX-2/5-LOX inhibitors”, European Journal of Medicinal Chemistry, 189, 112066, (2020), ISSN 0223-5234.
https://doi.org/10.1016/j.ejmech.2020.112066. IF: 5.573
- Heba T. Abdel-Mohsen, Ahmed M. El Kerdawy, Mohamed A. Omar, Emanuela Berrino, Ahmed S. Abdelsamie, Hoda I. El Diwani, Claudiu T. Supuran. “New thiopyrimidine-benzenesulfonamide conjugates as selective carbonic anhydrase II inhibitors: synthesis, in vitro biological evaluation, and molecular docking studies”, Bioorganic & Medicinal Chemistry, 28(5), 115329, (2020), ISSN 0968-0896.
https://doi.org/10.1016/j.bmc.2020.115329. IF: 3.073
- Zaki, N.G., Mahmoud, W.H., El Kerdawy, A.M.et al. “Structural characterization, thermal, DFT, cytotoxicity, and antimetastatic properties of cocaine complexes with La(III), Er(III), and Yb(III)”, Res Chem Intermed, 46, 3193–3216, (2020).
https://doi.org/10.1007/s11164-020-04146-3. IF: 2.262
- Abdel-Mohsen HT, Abd El-Meguid EA, El Kerdawy AM, Mahmoud AEE, Ali MM. “Design, synthesis, and molecular docking of novel 2-arylbenzothiazole multiangiokinase inhibitors targeting breast cancer”, Arch Pharm (Weinheim), 353(4), e1900340, (2020).
Doi: 10.1002/ardp.201900340. IF: 2.590
- Heba Abdelrasheed Allam, Enayat E. Aly, Ahmed K.B.A.W. Farouk, Ahmed M. El Kerdawy, Essam Rashwan, Safinaz E.S. Abbass. “Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents”, Bioorganic Chemistry, 98, 103726, (2020), ISSN 0045-2068.
https://doi.org/10.1016/j.bioorg.2020.103726. IF: 4.831
- Riham F. George, Manal Kandeel, Dina Y. El-Ansary, Ahmed M. El Kerdawy. “Some 1,3,5-trisubstituted pyrazoline derivatives targeting breast cancer: Design, synthesis, cytotoxic activity, EGFR inhibition and molecular docking”, Bioorganic Chemistry, 99, 103780, (2020), ISSN 0045-2068.
https://doi.org/10.1016/j.bioorg.2020.103780. IF: 4.831
- Abdel-Mohsen HT, Abdullaziz MA, El Kerdawy AM, Ragab FAF, Flanagan KJ, Mahmoud AEE, Ali MM, El Diwani HI, Senge MO. “Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles”, Molecules, 25(4), 770, (2020).
https://doi.org/10.3390/molecules25040770. IF: 3.267
- Mohammad M. Al-Sanea, Ahmed Elkamhawy, Sora Paik, Kyeong Lee, Ahmed M. El Kerdawy, Bukhari Syed Nasir Abbas, Eun Joo Roh, Wagdy M. Eldehna, Heba A.H. Elshemy, Rania B Bakr, Ibrahim Ali Farahat, Abdulaziz I. Alzarea, Sami I. Alzarea, Khalid S. Alharbi, Mohamed A. Abdelgawad. “Sulfonamide-based 4-anilinoquinoline derivatives as novel dual Aurora kinase (AURKA/B) inhibitors: Synthesis, biological evaluation and in silico insights”, Bioorganic & Medicinal Chemistry, 28(13), 115525, (2020), ISSN 0968-0896.
https://doi.org/10.1016/j.bmc.2020.115525. IF: 3.073
- Al-Warhi T, El Kerdawy AM, Aljaeed N, Ismael OE, Ayyad RR, Eldehna WM, Abdel-Aziz HA, Al-Ansary GH. “Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindole–Indole Conjugates as Anticancer CDK Inhibitors”, Molecules, 25(9), 2031, (2020).
https://doi.org/10.3390/molecules25092031. IF: 3.267
- Hadir Farouk, Muhammed A. Saad, Sawsan S. Mahmoud, Mohammed F. El-Yamany, Ola A. Sharaf, Rania F. Ahmed, Ezz E. El-Denshary. “Effect of (+) and (-) hydroxycitric acid sterio-isomers present in natural products in counteracting insulin resistance”, Egyptian Journal of Chemistry, 63(11), 4341-4354, (2020).
DOI: 10.21608/ejchem.2020.25054.2493. IF: 0.966
- Rasha R. Yossef, Mohamed F. Al-Yamany, Muhammed A. Saad, Ayman E. El-Sahar. “Neuroprotective effects of vildagliptin on drug induced Alzheimer’s disease in rats with metabolic syndrome: Role of hippocampal klotho and AKT signaling pathways”, European Journal of Pharmacology, 889, 173612, (2020), ISSN 0014-2999.
https://doi.org/10.1016/j.ejphar.2020.173612. IF: 3.263
- Ayman E. El-Sahar, Alyasaa A. Rastanawi, Muhammed F. El-Yamany, Muhammed A. Saad. “Dapagliflozin improves behavioral dysfunction of Huntington’s disease in rats via inhibiting apoptosis-related glycolysis”, Life Sciences, 257, 118076, (2020), ISSN 0024-3205.
https://doi.org/10.1016/j.lfs.2020.118076. IF: 3.647
- Hebatullah S. Helmy, Mahmoud A. Senousy, Ayman E. El-Sahar, Rabab H. Sayed, Muhammed A. Saad, Eman M. Elbaz. “Aberrations of miR-126-3p, miR-181a and sirtuin1 network mediate Di-(2-ethylhexyl) phthalate-induced testicular damage in rats: The protective role of hesperidin”, Toxicology, 433–434, 152406, (2020), ISSN 0300-483X.
https://doi.org/10.1016/j.tox.2020.152406. IF: 4.099
- Sandy N. Aziz, Alia A. Badawy, Demiana I. Nessem, Nevine S. Abd El Malak. “Promising nanoparticulate system for topical delivery of diphenhydramine hydrochloride: In-vitro and in-vivo evaluation”, Journal of Drug Delivery Science and Technology, 55, 101454, (2020), ISSN 1773-2247.
https://doi.org/10.1016/j.jddst.2019.101454. IF: 2.734
- Reham Waheed Hammad, Rania Abdel-Basset Sanad, Nevine Shawky Abdelmalak, Faisal A. Torad, Randa Latif. “New intranasal cross-linked mosapride xyloglucan pluronics micelles (MOS-XPMs) for reflux esophagitis disease: In-vitro optimization and improved therapeutic efficacy”, Journal of Advanced Research, 23, 83-94, (2020), ISSN 2090-1232.
https://doi.org/10.1016/j.jare.2020.01.013. IF: 6.992
- Farag, Michael M., Nevine S. Abd El Malak, Soad A. Yehia, and Mohammed A. Ahmed. “Sonocomplexation as an effective tool to enhance the antitumorigenic effect of metformin: Preparation, in vitro characterization, molecular dynamic simulation & MiaPaCa-2 cell line hypoxia evaluation.”, Journal of Drug Delivery Science and Technology, 59, 101968, (2020), ISSN 1773-2247.
https://doi.org/10.1016/j.jddst.2020.101968. IF: 2.734
- Louis, Mina M., Alia A. Badawy, Demiana I. Nessem, and Nevine S. Abd Elmalak. “Drotaverine hydrochloride gastroretentive floating mini-tablets: Formulation, in-vitro and in-vivo evaluation.”, Journal of Drug Delivery Science and Technology, 57, 101733, (2020), ISSN 1773-2247.
https://doi.org/10.1016/j.jddst.2020.101733. IF: 2.734
- Michael M. Farag, Nevine S. Abd El Malak, Soad A. Yehia, Mohammed A. Ahmed. “Sonocomplexation as an effective tool to enhance the antitumorigenic effect of metformin: Preparation, in vitro characterization, molecular dynamic simulation & MiaPaCa-2 cell line hypoxia evaluation”, Journal of Drug Delivery Science and Technology, 59, 101968, (2020), ISSN 1773-2247.
https://doi.org/10.1016/j.jddst.2020.101968. IF: 2.734
- Osman SM, Ayoub NA, Hafez SA, Ibrahim HA, El Raey MA, El-Emam SZ, Seada AA, Saadeldeen AM. “Aldose reductase inhibitor form Cassia glauca: A comparative study of cytotoxic activity with Ag nanoparticles (NPs) and molecular docking evaluation”, PLoS ONE, 15(10), e0240856, (2020).
https://doi.org/10.1371/journal.pone.0240856. IF: 2.740
- Trabik, Yossra A., Eman M. Moenes, Medhat A. Al-Ghobashy, Marianne Nebsen, and Miriam F. Ayad. “Analytical comparability study of anti-CD20 monoclonal antibodies rituximab and obinutuzumab using a stability-indicating orthogonal testing protocol: Effect of structural optimization and glycoengineering.”, Journal of Chromatography B, 1159, 122359, (2020), ISSN 1570-0232.
- Mohamed, Hadeer G., Medhat A. Al‐Ghobashy, Mervat A. Fouad, and Hala S. Zaazaa. “Quality Assessment of Lactoferrin in some Marketed Nutraceuticals Derived from Milk using Validated Analytical Methods.”, ChemistrySelect, 5(46), 14816-14825, (2020).
https://doi.org/10.1002/slct.202003681. IF: 1.811
- Omar NE, El-Fass KA, Abushouk AI, Elbaghdady N, Barakat AEM, Noreldin AE, Johar D, Yassin M, Hamad A, Elazzazy S, Dermime S. “Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review”, Front Immunol., 11, 1354, (2020).
Doi: 10.3389/fimmu.2020.01354. IF: 5.085
- Noha El Baghdady, Lamia Elwakeel, Mahmoud Ellithy, Nawal Hussein, Sara Shahin, Abdel Rahman El Naggar. “Efficacy and Safety of Sorafenib Versus Supportive Care in Egyptian Advanced Hepatocellular Carcinoma Patients”, Archives of Pharmaceutical Sciences Ain Shams University, 4(2), 224-236, (2020).
- Saad MAE, Fahmy MIM, Al-Shorbagy M, Assaf N, Hegazy AAE, El-Yamany MF. “Nateglinide Exerts Neuroprotective Effects via Downregulation of HIF-1α/TIM-3 Inflammatory Pathway and Promotion of Caveolin-1 Expression in the Rat’s Hippocampus Subjected to Focal Cerebral Ischemia/Reperfusion Injury”, Inflammation, 43(2), 401-416, (2020).
Doi: 10.1007/s10753-019-01154-3. IF: 3.212
- Hany H. Arab, Muhammed A. Saad, Ayman E. El-Sahar, Muhammad Y. Al-Shorbagy. “Mechanistic perspective of morin protection against ketoprofen-induced gastric mucosal injury: Targeting HMGB1/RAGE/NF-κB, DJ-1/Nrf2/HO-1 and PI3K/mTOR pathways”, Archives of Biochemistry and Biophysics, 693, 108552, (2020), ISSN 0003-9861.
https://doi.org/10.1016/j.abb.2020.108552. IF: 3.391
- Iman A.Y. Ghannam, Eman A. Abd El-Meguid, Islam H. Ali, Donia H. Sheir, Ahmed M. El Kerdawy. “Novel 2-arylbenzothiazole DNA gyrase inhibitors: Synthesis, antimicrobial evaluation, QSAR and molecular docking studies”, Bioorganic Chemistry, 93, 103373, (2019), ISSN 0045-2068.
https://doi.org/10.1016/j.bioorg.2019.103373. IF: 3.926
- Heba T. Abdel-Mohsen, Mohamed A. Omar, Ahmed M. El Kerdawy, Abeer E.E. Mahmoud, Mamdouh M. Ali, Hoda I. El Diwani. “Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors”, European Journal of Medicinal Chemistry, 179, 707-722, (2019), ISSN 0223-5234.
https://doi.org/10.1016/j.ejmech.2019.06.063. IF: 5.573
- El Kerdawy, A.M., Osman, A.A. & Zaater, M.A. “Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3β inhibitors”, J Mol Model,25(6), 171, (2019).
https://doi.org/10.1007/s00894-019-4032-5. IF: 1.346
- Somaia S. Abd El-Karim, Yasmin M. Syam, Ahmed M. El Kerdawy, Tamer M. Abdelghany. “New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: Synthesis, CDK2 inhibition, QSAR and molecular docking studies”, Bioorganic Chemistry, 86, 80-96, (2019), ISSN 0045-2068.
https://doi.org/10.1016/j.bioorg.2019.01.026. IF: 3.926
- Wagdy M. Eldehna, Ahmed M. El Kerdawy, Ghada H. Al-Ansary, Sara T. Al-Rashood, Mamdouh M. Ali, Abeer E. Mahmoud. “Type IIA – Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides”, European Journal of Medicinal Chemistry, 163, 37-53, (2019), ISSN 0223-5234.
https://doi.org/10.1016/j.ejmech.2018.11.061. IF: 5.573
- Eman M. Elbaz, Hebatullah S. Helmy, Ayman E. El-Sahar, Muhammed A. Saad, Rabab H. Sayed. “Lercanidipine boosts the efficacy of mesenchymal stem cell therapy in 3-NP-induced Huntington’s disease model rats via modulation of the calcium/calcineurin/NFATc4 and Wnt/β-catenin signalling pathways”, Neurochemistry International, 131, 104548, (2019), ISSN 0197-0186.
https://doi.org/10.1016/j.neuint.2019.104548. IF: 3.881
- Shendy, A.H., Eltanany, B.M., Al-Ghobashy, M.A. et al. “Coupling of GC-MS/MS to Principal Component Analysis for Assessment of Matrix Effect: Efficient Determination of Ultra-Low Levels of Pesticide Residues in Some Functional Foods”, Food Anal. Methods, 12, 2870–2885, (2019).
https://doi.org/10.1007/s12161-019-01643-z. IF: 2.667
- El-Sayed, Ghada M., Medhat A. Al-Ghobashy, Ali K. Attia, and Samah M. Kamal. “Nanoparticle-Enhanced Potentiometric Ion-Selective Electrodes for Therapeutic Drug Monitoring of Linezolid.”, Journal of The Electrochemical Society, 166 (14), 1-9, (2019).
DOI: 10.1149/2.1221913jes. IF: 3.721
- Hassan LA, Al-Ghobashy MA, Abbas SS. “Evaluation of the pattern and kinetics of degradation of adalimumab using a stability-indicating orthogonal testing protocol”, Biomed Chromatogr., 33(12), e4676, (2019).
Doi: 10.1002/bmc.4676. IF: 1.728
- Al-Ghobashy MA, Nadim AH, El-Sayed GM, Nebsen M. “Label-Free Potentiometric Ion Flux Immunosensor for Determination of Recombinant Human Myelin Basic Protein: Application to Downstream Purification from Transgenic Milk”, ACS Sens., 4(2), 413-420, (2019).
Doi: 10.1021/acssensors.8b01315. IF: 7.333
- Hassan, Lamiaa A., Sara M Shatat, Basma M Eltanany, Medhat A Al-Ghobashy, and Samah S Abbas. “Stability and biosimilarity assessment of infliximab using an orthogonal testing protocol and statistically-guided interpretation of peptide mapping”, Analytical methods,11 (25), 3198-3211, (2019).
Doi: 10.1039/c9ay00903e. IF: 2.596
- Ibrahim, F.A., Al-Ghobashy, M.A. & Abo-Elmagd, I.F. “Energy-efficient carbon-doped titanium dioxide nanoparticles: synthesis, characterization, and catalytic properties under visible LED irradiation for degradation of Gemifloxacin”, SN Appl. Sci.,1, 631, (2019).
- Muhammed A. Saad, Ayman E. El-Sahhar, Hany H. Arab, Muhammad Y. Al-Shorbagy. “Nicorandil abates arthritic perturbations induced by complete Freund’s adjuvant in rats via conquering TLR4-MyD88-TRAF6 signaling pathway”, Life Sciences, 218, 284-291, (2019), ISSN 0024-3205.
https://doi.org/10.1016/j.lfs.2019.01.002. IF: 3.647
- Radwan, A., El-Lakkany, N. M., William, S., El-Feky, G. S., Al-Shorbagy, M. Y., Saleh, S., & Botros, S. A. “Novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection”, Parasites Vectors, 12(1), 304, (2019).
- Choucry, A.M., Al-Shorbagy, M.Y., Attia, A.S. et al. “Pharmacological Manipulation of Trk, p75NTR, and NGF Balance Restores Memory Deficit in Global Ischemia/Reperfusion Model in Rats”, J Mol Neurosci,68(1), 78–90, (2019).
https://doi.org/10.1007/s12031-019-01284-1. IF: 2.678
- Muhammed A. Saad, Ayman E. El-Sahhar, Hany H. Arab, Muhammad Y. Al-Shorbagy. “Nicorandil abates arthritic perturbations induced by complete Freund’s adjuvant in rats via conquering TLR4-MyD88-TRAF6 signaling pathway”, Life Sciences, 218, 284-291, (2019), ISSN 0024-3205.
https://doi.org/10.1016/j.lfs.2019.01.002. IF: 3.647
- Hassan NF, Nada SA, Hassan A, El-Ansary MR, Al-Shorbagy MY, Abdelsalam RM. “Saroglitazar Deactivates the Hepatic LPS/TLR4 Signaling Pathway and Ameliorates Adipocyte Dysfunction in Rats with High-Fat Emulsion/LPS Model-Induced Non-alcoholic Steatohepatitis”, Inflammation, 42(3), 1056-1070, (2019).
Doi: 10.1007/s10753-019-00967-6. IF: 3.212
- Noha Abdel-Rahman, Maha H. Sharawy, Nirmeen Megahed, Mohammed S. El-Awady. “Vitamin D3 abates BDL-induced cholestasis and fibrosis in rats via regulating Hedgehog pathway”, Toxicology and Applied Pharmacology, 380, 114697, (2019), ISSN 0041-008X.
https://doi.org/10.1016/j.taap.2019.114697. IF: 3.347
- Marwa A. Fouad, Enas H. Tolba, Manal A. El-Shal, Ahmed M. El Kerdawy. “QSRR modeling for the chromatographic retention behavior of some β-lactam antibiotics using forward and firefly variable selection algorithms coupled with multiple linear regression”, Journal of Chromatography A, 1549, 51-62, (2018), ISSN 0021-9673.
https://doi.org/10.1016/j.chroma.2018.03.042. IF: 3.858
- Attallah, O.A., Al-Ghobashy, M.A., Nebsen, M. et al. “Assessment of pectin-coated magnetite nanoparticles in low-energy water desalination applications”, Environ Sci Pollut Res, 25, 18476–18483 (2018).
https://doi.org/10.1007/s11356-018-2060-9. IF: 2.914
- Medhat A. Al-Ghobashy, Samah M. Kamal, Ghada M. El-Sayed, Ali K. Attia, Mohamed Nagy, Ahmed ElZeiny, Marwa T. Elrakaiby, Mohammed M. Nooh, Maggie Abbassi, Ramy K. Aziz. “Determination of voriconazole and co-administered drugs in plasma of pediatric cancer patients using UPLC-MS/MS: A key step towards personalized therapeutics”, Journal of Chromatography B, 1092, 489-498, (2018), ISSN 1570-0232.
- Olivia A. Attallah, Medhat A. Al-Ghobashy, Ahmed Taha Ayoub, Marianne Nebsen. “Magnetic molecularly imprinted polymer nanoparticles for simultaneous extraction and determination of 6-mercaptopurine and its active metabolite thioguanine in human plasma”, Journal of Chromatography A, 1561, 28-38, (2018), ISSN 0021-9673.
https://doi.org/10.1016/j.chroma.2018.05.038. IF: 3.858
- Attallah OA, Al-Ghobashy MA, Ayoub AT, Tuszynski JA, Nebsen M. “Computer-aided design of magnetic molecularly imprinted polymer nanoparticles for solid-phase extraction and determination of levetiracetam in human plasma”, Rsc Advances, 8(26), 14280-92, (2018).
https://doi.org/10.1039/C8RA02379D. IF: 3.049
- Ali K. Attia, Medhat A. Al-Ghobashy, Ghada M. El-Sayed, Samah M. Kamal. “Voltammetric monitoring of linezolid, meropenem and theophylline in plasma”, Analytical Biochemistry, 545, 54-64, (2018), ISSN 0003-2697.
https://doi.org/10.1016/j.ab.2018.01.009. IF: 2.507
- Hoda E. Mohamed, Abeer A. Mohamed, Medhat A. Al-Ghobashy, Faten A. Fathalla, Samah S. Abbas. “Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocol”, Journal of Pharmaceutical and Biomedical Analysis, 150, 268-277, (2018), ISSN 0731-7085.
https://doi.org/10.1016/j.jpba.2017.12.022. IF: 2.983
- Sara M. Shatat, Basma M. Eltanany, Abeer A. Mohamed, Medhat A. Al-Ghobashy, Faten A. Fathalla, Samah S. Abbas. “Coupling of on-column trypsin digestion–peptide mapping and principal component analysis for stability and biosimilarity assessment of recombinant human growth hormone”, Journal of Chromatography B, 1072, 105-115, (2018), ISSN 1570-0232.
- Ibrahim, S.M., Al-Shorbagy, M.Y., Abdallah, D.M. et al. “Activation of α7 Nicotinic Acetylcholine Receptor Ameliorates Zymosan-Induced Acute Kidney Injury in BALB/c Mice”, Sci Rep, 8(1), 16814, (2018).
https://doi.org/10.1038/s41598-018-35254-1. IF: 4.011
- Rabab M. Ali, Muhammad Y. Al-Shorbagy, Maged W. Helmy, Hanan S. El-Abhar. “Role of Wnt4/β-catenin, Ang II/TGFβ, ACE2, NF-κB, and IL-18 in attenuating renal ischemia/reperfusion-induced injury in rats treated with Vit D and pioglitazone”, European Journal of Pharmacology, 15(831), 68-76, (2018), ISSN 0014-2999.
https://doi.org/10.1016/j.ejphar.2018.04.032. IF: 3.170
- Mohammed K. AbdElhameid, Madlen B. Labib, Ahmed T. Negmeldin, Muhammad Al-Shorbagy & Manal R. Mohammed, “Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors”, Journal of Enzyme Inhibition and Medicinal Chemistry, 33(1), 1472-1493, (2018).
DOI: 10.1080/14756366.2018.1503654. IF: 4.027
- Abd Elhameid MK, Ryad N, Al-Shorbagy MY, Mohammed MR, Ismail MM, El Meligie S. “Design, Synthesis and Screening of 4,6-Diaryl Pyridine and Pyrimidine Derivatives as Potential Cytotoxic Molecules”, Chem Pharm Bull, 66(10), 939-952. (2018).
Doi: 10.1248/cpb.c18-00269. IF: 1.405
- Ibrahim, F.A., Al-Ghobashy, M.A., Abd El-Rahman, M.K. et al. “Optimization and in line potentiometric monitoring of enhanced photocatalytic degradation kinetics of Gemifloxacin using TiO2 nanoparticles/H2O2”. Environ Sci Pollut Res, 24, 23880–23892 (2017).
https://doi.org/10.1007/s11356-017-0045-8. IF: 2.800
- Heba S. Abed, Medhat A. Al-Ghobashy, Faten A. Fathalla, Maissa Y. Salem. “Evaluation of the combined effects of pegylation and glycosylation on the stability of erythropoietin using a stability-indicating SE-HPLC”, Biologicals, 50, 129-136, (2017), ISSN 1045-1056.
- Moenes, Eman M., Medhat A Al-Ghobashy, Abeer A Mohamed, and Maissa Y Salem. “Comparative Assessment of the Effect of Glyco-engineering on the Pattern and Kinetics of Aggregate Formation of Darbepoetin Alfa using a Stability-Indicating Orthogonal Testing Protocol”, Journal of Chromatography B, 1072, 405-414, (2017), ISSN 1570-0232.
Doi: 10.1016/j.jchromb.2017.10.057. IF: 2.441
Tuition Fees & Deadlines
School of Pharmacy tuition fees for the academic year (2021-2022): EGP 110,000 for Egyptian students. For more information please click here.
This academic year, a good number of scholarships are being offered for applicants. For more information on the scholarships, please click here.
The deadline for the academic year 2021/2022 is 15 September.